AzurRx BioPharma, Inc. (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, this morning announced that, in partnership with French pharmaceutical firm Mayoly Spindler, it has enrolled three new patients to its phase IIA study of MS1819-SD for patients with exocrine pancreatic insufficiency caused by chronic pancreatitis. With these additions, the total number of patients enrolled in the trial is nine, and, with an enrollment target of 12-15 patients, AzurRx expects to complete enrollment in the first half of 2018. “We are very pleased that our existing clinical sites have recruited these new patients,” Thijs Spoor, CEO of AzurRx, stated in the news release. “After a rapid clearance of the Investigational Medicinal Product Dossier (IMPD) for our site in France (La Timone Hospital, Marseille), we believe have now identified enough potential patients to complete enrollment of the study in the first half of 2018, in line with previously published guidance.”
To view the full press release, visit http://nnw.fm/3VkGo
About AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc. is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the Company’s lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infections. The Company is headquartered in Brooklyn, NY, with scientific operations based in Langlade, France. Additional information regarding the Company can be found at www.AzurRx.com
More from NetworkNewsBreaks
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com